Laurence Reid - 25 Feb 2022 Form 4 Insider Report for Decibel Therapeutics, Inc.

Role
President and Chief Executive Officer, Director
Signature
/s/ Elisabeth Leiderman, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
25 Feb 2022
Net transactions value
$0
Form type
4
Filing time
28 Feb 2022, 15:36:36 UTC
Previous filing
17 Sep 2021
Next filing
17 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DBTX Stock Options (right to buy) Award $0 +187,500 $0.000000 187,500 25 Feb 2022 Common Stock 187,500 $3.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 25, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 25, 2023 and with respect to the remainder in 36 equal monthly installments thereafter through February 25, 2026.

Remarks:

President and Chief Executive Officer